Keymed Biosciences Inc. has announced the publication of the latest clinical trial results for their bispecific antibody treatment, CM336, in the New England Journal of Medicine. Conducted by Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, the study reports on the efficacy of CM336 in treating patients with refractory autoimmune hemolytic anemia (AIHA) following CD19 CAR T-Cell Therapy. Two patients showed rapid disease improvement, achieving partial remission within days and maintaining sustained remission for over six months without further immunosuppressive therapies. The study highlights CM336's potential as a treatment option, demonstrating positive efficacy signals and a favorable safety profile.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。